Dow Jones
39.886,09 +327,98 (+0,83%) Nasdaq
16.742,50 +231,32 (+1,40%) Nikkei 225
38.385,73 +29,67 (+0,08%) EUR/USD
1,0884 +0,0062 (+0,58%) Bitcoin EUR
60.895,44 +4.295,24 (+7,59%) CMC Crypto 200
1.390,48 +122,54 (+9,67%)
ADPT Oct 2024 5.000 put
| Chiusura precedente | 1,7300 |
| Aperto | 1,7300 |
| Denaro | 0,0000 |
| Lettera | 2,7500 |
| Prezzo d'esercizio | 5,00 |
| Scadenza | 2024-10-18 |
| Min-Max giorno | 1,7300 - 1,7300 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 17 |
GlobeNewswireAdaptive Announces Launch of Epic Integration for clonoSEQ®
The Adaptive-Epic integration will provide clinicians and patients with easier access to minimal residual disease (MRD) monitoring in blood cancersSEATTLE, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ® is now available to health care providers as a fully integrated
- GlobeNewswire
Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference in New York, New York Adaptive Biotechnologies’ management is scheduled to participate in a fireside
- GlobeNewswire
Adaptive Biotechnologies Reports Second Quarter 2023 Financial Results
SEATTLE, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2023. “We had another strong quarter with clonoSEQ test volume growth of 52% versus prior year and the first FDA IND acceptance in cancer cell therapy
